CDT Equity Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jamie Bligh
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4581 Tamiami Trail North Naples FL United States of America 34103
- IPO Date
- Mar 28, 2022
- CIK
- 0001896212
- Website
- cdtequity.com
- Similar Companies
- Business
- CDT Equity Inc. is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company develops clinical-stage pharmaceutical products targeting unmet medical needs in autoimmune disorders, idiopathic male infertility, dermatology, oncology, and animal health. Its product pipeline includes glucokinase activators and myeloperoxidase inhibitors with candidates prepared for Phase II clinical trials. CDT leverages advanced solid-form chemistry and co-crystallization technologies to improve drug properties and extend patent life by up to 20 years. The company employs artificial intelligence-powered disease mapping and asset repositioning strategies to accelerate development timelines and optimize clinical assets that have been deprioritized by larger pharmaceutical companies. Headquartered in Cambridge, UK, and publicly traded on NASDAQ under the ticker CDT, the company was formerly known as Conduit Pharmaceuticals Inc. CDT recently rebranded to reflect an expanded focus on being a data-driven biotech platform. Major recent developments include an exclusive license agreement with AstraZeneca to develop and commercialize AZD1656 and AZD5658 glucokinase activators targeting autoimmune diseases and AZD5904, a myeloperoxidase inhibitor targeting idiopathic male infertility. CDT also entered a strategic services agreement with Agility Life Sciences to develop new enhanced solid oral dosage forms for its autoimmune pipeline, supported by robust intellectual property. It has adopted a cryptocurrency treasury reserve strategy to diversify its balance sheet, partnering with Sarborg to implement an AI-led system for cryptocurrency market evaluation. The company also executed a 1-for-8 reverse stock split in 2025 to increase fundraising potential and maintain capital efficiency. CDT operates with a lean, asset-agnostic model to prioritize speed and adaptability while focusing on licensing and commercialization partnerships after preclinical studies. CDT Equity Inc. was originally founded as Conduit Pharmaceuticals and operates primarily in the biopharmaceutical industry, serving markets in the US, UK, and globally through its AI-driven, innovative drug development platform. Its strategy focuses on unlocking value from clinical-stage compounds with Phase I safety data using a combination of AI, solid-form chemistry, and strategic alliances to bring novel treatments to market. Recent expansions include efforts in animal health through partnerships and continued growth in digital asset management integrated with its biotech development platform. The company retains a portfolio addressing a broad therapeutic spectrum including inflammatory and autoimmune conditions, male infertility, and dermatology. Its Cambridge-based facilities and scientific resources are crucial in advancing co-crystallization technologies and AI-driven drug repurposing that enhance market protection and extend drug lifecycle. CDT Equity Inc. exemplifies a modern biotech entity blending pharmaceutical development with digital innovation for efficient asset progression and commercialization readiness.
Company News
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
CDT Environmental Technology Announces Results of Extraordinary General Meeting
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
CDT Equity Inc. Announces Reverse Stock Split
CDT Environmental Technology Investment Holdings Regains Compliance with Nasdaq Minimum Bid Price Requirement
CDT Environmental Technology Investment Holdings Limited to Hold Extraordinary General Meeting on July 28, 2026
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
CDT Equity Stock Gets A Boost On SarborgQ Development News
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
CDT Equity Announces Debt Update and New Loan Facility
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
CDT Environmental Technology Investment Holdings Limited Announces Share Consolidation
CDT Announces Canadian Patent for AZD5904 in Male Infertility